Drug Development Pipeline
AR-501 (Panaecin™) is an inhaled formulation of gallium. Gallium is a molecule, nearly identical to iron, that disrupts iron-dependent biological processes and has been shown to kill antibiotic-resistant strains of Pseudomonas aeruginosa in laboratory research.
Gallium can also be administered intravenously. Intravenous (IV) gallium has already been approved by the FDA for use in people and is now being studied for its safety and effectiveness in controlling infections in people with CF.
A Phase 1 study of AR-501 in healthy volunteers showed that the drug was well-tolerated. A Phase 2 study of AR-501 in people with CF was recently completed.
This program is sponsored by Aridis Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Recent AR-501 (Panaecin™) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More